Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Simufilam 100 mg Tablets in Participants With Mild to Moderate Alzheimer's Disease

NCT05575076 is registered in ClinicalTrials.gov with Cassava Sciences, Inc. as lead sponsor.

NCT NCT05575076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05575076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Simufilam 100 mg Tablets in Participants With Mild to Moderate Alzheimer's Disease
Lead sponsor
Cassava Sciences, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
November 7, 2022
Completion date
January 31, 2025
Enrollment
1,081 (actual)
Sites
134

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease